Eupraxia Pharmaceuticals Inc. Announces Presentation at the Raymond James Human Health Innovations Conference

·1 min read

VICTORIA, BC, June 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that senior management will deliver a corporate presentation on June 23, 2021, at 2:00 p.m. ET at the Virtual Raymond James Human Health Innovations Conference.

Interested parties can view the live presentation online by clicking the following link:

https://kvgo.com/rj-health/eupraxia-pharmaceuticals-inc-june-2021

A replay of the presentation will be available on the investor relations section of the Company's website here: https://eupraxiapharma.com/investors/events-and-presentations/default.aspx

About Eupraxia

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com

SOURCE Eupraxia Pharmaceuticals Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/June2021/16/c0973.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting